On October 3, the specialists of Biokhimik PJSC produced the first experimental and industrial lot of antibiotic substance for Vancomycin. This was yet another step for the region in the implementation of policy aimed at import substitution and ensuring drug provision security for Russia.
The efforts by the specialists from Mordovia to address this key objective will allow Russian manufacturers not to import the same substance from Europe and the United States and reduce the cost of many drugs.
The industrial manufacturing and the launch of new generation antibiotic onto the Russian market will start after the studies of substance that are required for its further certification, said Pyotr Bely, the Chairman of the Board of Directors of PROMOMED Management Company LLC.
This summer, the specialists of Biokhimik for the first time produced in their lab the active substance of world-renowned antibiotics.
According to Pyotr Bely, the Chairman of the Board of Directors of PROMOMED Management Company LLC, by the end of 2017, Biokhimik will manufacture four antibiotic substances of latest generation entirely made of Russian raw materials. The implemented investment program also provides for establishing a full manufacturing cycle ranging from the substance to finished drug, which will meet all international standards.